EUVIMEDEUVIMED entdecken
Open Access · CC0

How much is too much? A medication use evaluation of VA ICU sedation practice during the COVID-19 pandemic

Ian C Murphy, Kelly Bryan, Muriel Burk iD, Rong Jiang, Francesca Cunningham, Sarah Providence, Elizabeth Rightnour, Sarah Zavala iD, Kathleen Morneau, Trisha Exline, Stacey Rice, Travis Schmitt und 14 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0340225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Ian C Murphy und 25 weiteren Autor:innen. Beteiligte Einrichtung: Yale University School of Medicine, New Haven, Connecticut, United States of America. Hauptthemen laut MEDLINE: COVID-19, Intensive Care Units, Hypnotics and Sedatives. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES Early data suggested higher sedative requirements for ventilated COVID+ patients, deviating from established guidelines. We assessed the relationship between sedative use and outcomes in mechanically ventilated Veterans during the COVID-19 pandemic.

Design

Retrospective Medication Use Evaluation Setting National Sample of 13 Distinct VA Medical Center Intensive Care Units Patients Critically ill Veteran patients requiring mechanically ventilation for ≥2 days Interventions None. Measurements and main results The proportion of patients receiving fentanyl, midazolam and propofol was higher during COVID years. Compared with pre-COVID, median fentanyl dose was higher during Years 1 and 2 (1575mcg [(IQR) 1000–1650] vs. 1900 [1250–3000] vs. 1910 [1150–3500]). Adjuvant antipsychotics use was relatively low but tended to increase over time (pre = 10.5% vs. Year 1 = 12.3% vs. Year 2 = 14.1%). Most patients started on antipsychotics in the ICU were continued on the drug after extubation. Mortality was higher during COVID years (pre = 26.9% vs. 1 = 36.8% and 2 = 35.9%). In stratified analyses by COVID status years 1–2 (n = 79, 27%), a higher proportion of COVID+ patients received fentanyl (96% vs. 84%) and propofol (90% vs. 77%) and at higher doses (fentanyl = 1650mcg vs. 2688mcg median cumulative dose; propofol maximum infusion rate = 30 mc/kg/min (20–50) vs. 40 (25–50)). Sedative doses were similar to pre-COVID among non-COVID patients. Anti-psychotics were more frequently continued post extubation among COVID+ (34.6% vs. non-COVID+=14.9%). COVID+ patients were also less likely to have awakening and breathing trials at 48 hours after intubation (18% vs. 46%).

Conclusions

Sedative use and dosing increased during the first two years of COVID compared to pre-COVID, especially for COVID+ patients. The sustained elevated levels of fentanyl use in Year 2 suggests possible ‘therapeutic creep’ away from guideline-concordant practices for COVID+ patients. Antipsychotic prescription during intubation and following extubation was also more common among COVID + . These findings could inform development and implementation of safer sedation practices across VA ICUs during respiratory pandemics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Intensive Care UnitsHypnotics and SedativesHumansMaleFemaleRetrospective StudiesAgedFentanylMiddle AgedRespiration, ArtificialPropofolSARS-CoV-2MidazolamPandemicsUnited States

Substanzen

Hypnotics and SedativesFentanylPropofolMidazolam

Autor:innen und Institutionen

  • Yale University School of Medicine, New Haven, Connecticut, United States of America.
  • Veterans Affairs Center for Medication Safety-Pharmacy Benefits Management ServicesWashington, District of Columbia, United States of America.
  • Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States of America.
  • Newton D. Baker VA Medical Center, Martinsburg, West Virginia, United States of America.
  • Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, United States of America.
  • South Texas Veterans Health Care System, San Antonio, Texas, United States of America.

ORCID-Profile: Muriel Burk, Sarah Zavala, Kathleen M Akgün

Zitieren

APA

Murphy, I. C., Bryan, K., Burk, M., Jiang, R., Cunningham, F., Providence, S., Rightnour, E., Zavala, S., Morneau, K., Exline, T., Rice, S., Schmitt, T., Drumright, K., Lee, J., Davids, B., Guilbeault, T., Klenosky, B., Sutherland, A. M., Rosen, A., …, & Akgün, K. M. (2025). How much is too much? A medication use evaluation of VA ICU sedation practice during the COVID-19 pandemic. PLOS One. https://doi.org/10.1371/journal.pone.0340225

Vancouver

Murphy IC, Bryan K, Burk M, Jiang R, Cunningham F, Providence S, et al. How much is too much? A medication use evaluation of VA ICU sedation practice during the COVID-19 pandemic. PLOS One. 2025. doi:10.1371/journal.pone.0340225

BibTeX
@article{Murphy2025,
  author = {Murphy, Ian C and Bryan, Kelly and Burk, Muriel and Jiang, Rong and Cunningham, Francesca and Providence, Sarah and Rightnour, Elizabeth and Zavala, Sarah and Morneau, Kathleen and Exline, Trisha and Rice, Stacey and Schmitt, Travis and Drumright, Kelly and Lee, Jennifer and Davids, BreAnna and Guilbeault, Tram and Klenosky, Brooke and Sutherland, Ann-Marie and Rosen, Abbie and Ratliff, Lauren and Bukowski, Kenneth and Pisani, Margaret A and Franck, Andrew and Wong, Mark and Witcher, Preston and Akgün, Kathleen M},
  title = {How much is too much? A medication use evaluation of VA ICU sedation practice during the COVID-19 pandemic},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0340225}
}
Kostenlos starten →